project . 2019 - 2019 . Closed

ABOPEN

FIRST INSTANT, OFF-THE-LAB AND USER-FRIENDLY BLOOD GROUPING TEST
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 868361 Call for proposal: H2020-SMEInst-2018-2020-1
  • Funded under: H2020 | SME-1 Overall Budget: 71,429 EURFunder Contribution: 50,000 EUR
  • Status: Closed
  • Start Date
    01 May 2019
    End Date
    31 Aug 2019
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Despite being eradicated from the developed world, the Rhesus Disease or HDFN (Hemolytic Disease of the Fetus and Newborn), a disease where the immune system from the mother attacks the red blood cells from their babies, still kills 141,000 children and mothers in developing regions every year. Deaths that could be easily prevented by screening pregnant women for their RhD factor type. Although 15% of RhD(-) women are at risk, 220 million women in developing countries should be tested, since the majority do not know their RhD factor type. At Eldon Biologicals AS (a Danish company created in 2002), we are a profitable company that has already sold millions of Eld...
Description
Despite being eradicated from the developed world, the Rhesus Disease or HDFN (Hemolytic Disease of the Fetus and Newborn), a disease where the immune system from the mother attacks the red blood cells from their babies, still kills 141,000 children and mothers in developing regions every year. Deaths that could be easily prevented by screening pregnant women for their RhD factor type. Although 15% of RhD(-) women are at risk, 220 million women in developing countries should be tested, since the majority do not know their RhD factor type. At Eldon Biologicals AS (a Danish company created in 2002), we are a profitable company that has already sold millions of Eld...
Any information missing or wrong?Report an Issue